Obermatt
See Similar Stocks →

Editas Medicine

NSQ:EDIT · US28106W1036
BiotechnologySmall

360

11
Profit price45
Owner Earnings Yield1
Dividend Yield1
Price/Sales31
Price/Book81
Return on Capital13
Cash Return on Capital1
Return on Equity6
EBIT Margin10
Gross Profitability11
Accruals84
Owner Earnings Margin26
Sales growth13
Profit growth50
Reinvestment78
Price momentum49
Debt load9
Refinancing29
Debt Payback1
Liquidity43
Analyst ratings13
Opinion Changes50
Price Target Upside67
Market mood8
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Editas Medicine doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2013
Employees157
Websiteeditasmedicine.com
ISINUS28106W1036
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Stem Cell TherapyHematologyGeneticsArtificial IntelligenceGenetic DisorderOncologyBiotechnologyHealth CareMedical

Description

Editas Medicine, Inc. (Editas Medicine) operates as a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company’s core capability in gene editing uses…

Analysis

Weak and unloved

Editas Medicine, Inc. scores below average on quality and is priced accordingly, a low-conviction position in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 4/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
7
2026

All-time high

24

Mar 2026

All-time low

7

Jun 2026

Average rank

16

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
31
—
—
—
Price/Earnings
55
—
—
—
Price/Book
81
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
47
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Editas Medicine with its peers
Intellia Therapeutics
NMQ:NTLA
25
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Beam Therapeutics
NSQ:BEAM
17
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Vertex Pharmaceuticals
NSQ:VRTX
63
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Century Therapeutics
NAQ:IPSC
45
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Caribou Biosciences
NSQ:CRBU
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MacroGenics
NSQ:MGNX
24
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →